Press releases and news
2021
Camurus receives Carnegie Sustainability Award 2021
Camurus announces publication showing superior patient treatment satisfaction with Buvidal® weekly and monthly depot injections in opioid dependence
Resolutions at the annual general meeting 2021 in Camurus
Camurus’ Interim Report January-March 2021
The Australian TGA approves key label updates to Buvidal® for treatment of opioid dependence
Camurus Annual Report for 2020
Notice of annual general meeting 2021 in Camurus AB (publ)
Camurus receives positive CHMP opinion for Buvidal 160mg monthly dose for the treatment of opioid dependence
Camurus’ Full Year Report 2020
Change in number of shares and votes in Camurus
Camurus appoints Andrew McLean as Vice President Corporate Development and Senior Counsel
2020
Change in number of shares and votes in Camurus
Swissmedic approves Buvidal for the treatment of opioid dependence
Exercise of Camurus’ subscription warrant program 2017/2020
Camurus announces outcome of the arbitration process with Braeburn
Camurus announces that Braeburn receives Complete Response Letter for Brixadi for opioid use disorder in the US
Change in number of shares and votes in Camurus
Camurus’ Interim Report Third Quarter 2020
Camurus’ Nomination Committee appointed for the Annual General Meeting 2021
Change in number of shares and votes in Camurus
Get the latest news from Camurus
Subscribe to receive latest news from Camurus directly to your email.